Table 1 Patient demographics and clinical characteristics
Characteristic | Patients n = 64a |
|---|---|
Age, median | 60.75 |
Sex, n (%) | |
 Female | 35 (54.69%) |
 Male | 29 (45.31%) |
Cohort, n (%) | |
 A. Head and neck | 11 (17.19%) |
  HPV+ | 4 (36.36%) |
  HPV- | 1 (9.09%) |
  Unknown | 4 (36.36%) |
  Missing | 2 (18.18%) |
 B. Breast | 10 (15.63%) |
 C. Ovarian | 10 (15.63%) |
 D. Melanoma | 8 (12.50%) |
 E. Mixed solid tumors | 25 (39.06%) |
Best overall response, n (%) | |
 Complete response | 2 (3.13%) |
 Partial response | 13 (20.31%) |
 Stable disease | 16 (25.00%) |
 Progressive disease | 33 (51.56%) |
Biomarkers | |
 PD-L1 expression, mean % (SD) | 16.16% (32.40%) |
 PD-L1 subgroups, n (%) | |
  <1% | 33 (51.56%) |
  1–49% | 22 (34.38%) |
  ≥50% | 9 (14.06%) |
Tumor mutational burden, mean (SD)b | 13.61 (52.58) |
